Home » Biogeneric Approval Pathway Could Save Billions, CBO Says
Biogeneric Approval Pathway Could Save Billions, CBO Says
Government healthcare plans such as Medicare and Medicaid could save more than $10 billion over about a decade under a modified approval pathway for follow-on biologics (FOBs), according to a Congressional Budget Office (CBO) report. The CBO estimates that if Congress established a pathway to approve FOBs, allowing innovators to have about 12 years of exclusivity, the increased competition would put downward pressure on prices.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
07May
-
14May
-
30May